Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Autophagy Deficiency Diminishes Indomethacin-Induced Intestinal Epithelial Cell Damage through Activation of the ERK/Nrf2/HO-1 Pathway

Satoshi Harada, Takatoshi Nakagawa, Shunichi Yokoe, Shoko Edogawa, Toshihisa Takeuchi, Takuya Inoue, Kazuhide Higuchi and Michio Asahi
Journal of Pharmacology and Experimental Therapeutics December 2015, 355 (3) 353-361; DOI: https://doi.org/10.1124/jpet.115.226431
Satoshi Harada
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takatoshi Nakagawa
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunichi Yokoe
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoko Edogawa
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshihisa Takeuchi
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuya Inoue
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhide Higuchi
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michio Asahi
Departments of Internal Medicine II (S.H., S.E., T.T., T.I., K.H.) and Pharmacology (T.N., S.Y., M.A.), Faculty of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Role of Atg5 in injury of the small intestine after IM treatment in vitro and in vivo. (A and B) Gross appearance of intestinal lesions (A) and ulcer index values (B) after IM administration in WT and conditional Atg5KO mice. Arrows indicate epithelial erosion caused by IM-induced intestinal injuries. Ulcer index values are expressed as means ± S.E. (n = 5). (C) Cytotoxicity was estimated after treatment with various concentrations of IM in IEC6 and IEC6shAtg5 cells. Open bars, IEC6 cells; closed bars, IEC6shAtg5 cells. Statistical analysis was performed using Tukey’s method. *P < 0.05.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Induction of autophagy and subsequent apoptosis by IM treatment in IEC6 cells, not in IEC6shAtg5 cells. The cells were treated with 200 μM IM for various durations (0, 1, 2, 4, 8, and 12 hours). (A) LC3 expression levels at each time point in IEC6 cells and IEC6shAtg5 cells were determined using Western blot analyses. The arrow and arrowhead indicate LC3-I and LC3-II, respectively. (B) The cleavage of PARP1 in IM-treated IEC6 cells and IEC6shAtg5 cells was determined. The arrow and arrowhead indicate intact and cleaved PARP1, respectively.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    ROS generation before and after IM treatment in IEC6 and IEC6shAtg5 cells. (A and B) Both total ROS and superoxide were estimated before and after treatment with 200 μM IM in IEC6 and IEC6shAtg5 cells using a Total ROS/Superoxide Detection Kit (Enzo Life Sciences Inc.). The effect of N-acetyl cysteine (NAC) was evaluated to confirm that the assay was suitable. (C and D) The changing rates of relative ROS or superoxide production after various concentrations (0, 50, 100, or 200 μM) of IM treatment were estimated in both cells and compared with each other. *P < 0.05; **P < 0.01.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Quantitative evaluation of functionally active mitochondria before and after IM treatment in IEC6 cells and IEC6shAtg5 cells. Mitochondria staining with MitoTracker Red CMXRos, a membrane potential dependent mitochondria probe. Cells were preincubated with or without 200 μM IM for 1 h; then, MitoTracker Red CMXRos was added, and further incubated for 1 h. The fluorescence was measured using GloMax (Promega). *P < 0.05; Tukey’s test.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Changes in protein expression levels after IM treatment in IEC6 and IEC6shAtg5 cells. The cells were treated with 200 μM IM for the indicated times. (A and B) Protein expression levels of total and phosphorylated ERK (A) and Nrf2 and HO-1 (B) at each time point after IM treatment in IEC6 and IEC6shAtg5 cells were determined using Western blot analyses.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Involvement of ROS in IM-induced autophagy, subsequent apoptosis, and the ERK/Nrf2/HO-1 pathway. After the preincubation with or without 10 μM MnTMPyP for 30 minutes, IEC6 cells were treated with 200 μM IM for another 2 hours. (A and B) Cleavage of LC3 (A) or PARP1 (B) was determined using Western blot analyses. Arrows indicate LC3-I (A) or intact PARP1 (B), and arrowheads indicates LC3-II (A) or cleaved PARP1 (B). (C) Using the same samples, the levels of ERK phosphorylation, Nrf2 stabilization, and HO-1 induction were determined using Western blot analyses. (D) After preincubation with or without 1 μM MnTMPyP for 30 minutes, IEC6 cells were treated with 200 μM IM for another 2 hours. Nrf2 promoter activity was evaluated by a luciferase assay. *P < 0.01.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Effects of autophagy deficiency and IM administration on the ERK/Nrf2/HO-1 pathway in small intestinal mucosa. WT and Atg5 KO mice were treated with or without IM administration orally. After 24 hours, small intestines (stomach to ileum) of the euthanized animals were excised, and the mucosa was surgically scraped. The scraped tissues were collected and analyzed with Western blot analyses. *P < 0.05.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    Possible mechanism for the amelioration of IM-induced intestinal epithelial cell injury by autophagy deficiency. (A) In normal cells, oxidative stress is suppressed by autophagy; therefore, the ERK/Nrf2/HO-1 pathway is not activated under basal conditions. After IM treatment, the cells cannot fully prevent apoptosis-induced cell damage due to the increase of oxidative stress. (B) In autophagy-deficient cells, the ERK/Nrf2/HO-1 pathway is activated by oxidative stress even under basal conditions. The cells can minimize apoptosis-induced cell damage after IM treatment, because it is more resistant to oxidative stress due to the upregulated ERK/Nrf2/HO-1 pathway.

Tables

  • Figures
    • View popup
    TABLE 1

    Effect of autophagy deficiency with or without IM treatment on IEC6 cells or mouse intestinal epithelial cells

    MiceEpithelial Cell DamageAutophagyApoptosisOxidative StressERK/Nrf2/HO-1
    WT—++++
    WT + IM++++++++++++++
    Atg5 KO——+++++
    Atg5 KO + IM+—++++++++
    • — : not detectable; + : low; ++ : medium; +++ : high.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 355 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 355, Issue 3
1 Dec 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Autophagy Deficiency Diminishes Indomethacin-Induced Intestinal Epithelial Cell Damage through Activation of the ERK/Nrf2/HO-1 Pathway
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Amelioration of Indomethacin-Induced Injury by Autophagy Deficiency

Satoshi Harada, Takatoshi Nakagawa, Shunichi Yokoe, Shoko Edogawa, Toshihisa Takeuchi, Takuya Inoue, Kazuhide Higuchi and Michio Asahi
Journal of Pharmacology and Experimental Therapeutics December 1, 2015, 355 (3) 353-361; DOI: https://doi.org/10.1124/jpet.115.226431

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Amelioration of Indomethacin-Induced Injury by Autophagy Deficiency

Satoshi Harada, Takatoshi Nakagawa, Shunichi Yokoe, Shoko Edogawa, Toshihisa Takeuchi, Takuya Inoue, Kazuhide Higuchi and Michio Asahi
Journal of Pharmacology and Experimental Therapeutics December 1, 2015, 355 (3) 353-361; DOI: https://doi.org/10.1124/jpet.115.226431
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Increased momentary urethral closure by 5-HT2C agonist
  • Canalicular Transporters Studied with Fluorescent Bile Acids
  • Knockout of Add3 Promotes L-NAME–Induced Renal Injury
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics